Becton Dickinson & Co. (NYSE:BDX) missed the consensus sales forecast for its fiscal second quarter and cut its outlook for the rest of the year, sending its share price down today on Wall Street.
The cut to its earnings guidance is due to “recent regulatory and market pressures related to paclitaxel-coated devices,” Franklin Lakes, N.J.-based BD said. In March, the FDA warned on the risk of increased long-term mortality in peripheral artery disease patients treated with paclitaxel-coated devices like the Lutonix balloon BD acquired along with C.R. Bard in December 2017.
